Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 2/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ESRRA | P11474 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683750 | 0.84 | MAPK14 (0.33) | ESRRACTNNB1WNT3APAK1PARP1 | |
| SCHEMBL1683712 | 0.81 | GAA (0.46) | — | |
| SCHEMBL4422771 | 0.80 | TUBB1 (0.40) | — | |
| SCHEMBL1683758 | 0.79 | CNR2 (0.52) | CNR2ADORA3ADORA2AADORA1RXFP1 | |
| SCHEMBL4428560 | 0.79 | NPSR1 (0.38) | RXFP1CHEK2NPSR1NPC1RAB9A | |
| SCHEMBL4427216 | 0.79 | CNR2 (0.47) | CNR2RXFP1CHRM2CHRM4CHRM5 | |
| SCHEMBL1683602 | 0.79 | CNR2 (0.44) | CNR2CDK1CDK4CCND1CDK2 | |
| SCHEMBL1683771 | 0.78 | CNR2 (0.46) | CNR2PARP1HTTNPC1RAB9A | |
| SCHEMBL4424310 | 0.77 | FGFR2 (0.38) | CNR2HTTRAB9A | |
| SCHEMBL4418724 | 0.71 | ALDH1A1 (0.37) | HTTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865196-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-12-15 | — | — | US | disclosed |
| US-10301285-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190092755-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2019-03-28 | — | — | US | disclosed |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2018-04-05 | — | — | US | disclosed |
| EP-3289876-A1 | COMPOUNDS FOR TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-2959900-A1 | COMPOUND FOR TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2015-12-30 | — | — | EP | disclosed |
| US-9029408-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8592465-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-11-26 | — | — | US | disclosed |
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | HCCS, NQO1, CCNY | CNR2 495/4885ADORA3 1240/4885ADORA2A 991/4885 |
| US-10865196-B2 | Compounds for treatment of cancer | CYP19A1, CYP17A1, SOX18 | CNR2 3924/4885ADORA3 4183/4885ADORA2A 3648/4885 |
| US-10301285-B2 | Compounds for treatment of cancer | CYP19A1, CYP17A1, SOX18 | CNR2 3924/4885ADORA3 4183/4885ADORA2A 3648/4885 |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | CNR2 3924/4885ADORA3 4183/4885ADORA2A 3648/4885 |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | CNR2 3924/4885ADORA3 4183/4885ADORA2A 3648/4885 |
| US-20190092755-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | CNR2 3924/4885ADORA3 4183/4885ADORA2A 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.